



CLAIMS

1. A compound of formula (I)




- 5 or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein
- R₁ is a C₃₋₈alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C₁₋₃alkyl, or C₁₋₃alkoxy,
 - the carbon of R₁ bonded to the amine in the 4-position of the quinazoline is in (*R*)-configuration,
 - R₂ is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile,
 - R₃ is hydrogen or deuterium,
 - R₄ is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C₄₋₇heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C₄₋₇heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl,
- 20 and
- R₅ is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R₂, R₃, R₄ and R₅ is not hydrogen.
- 25 **2.** The compound of claim 1, wherein R₁ is a C₄₋₈ alkyl substituted with a hydroxyl.

3. The compound of claim 1 or 2, wherein R₁ is of formula (II):




or of formula (III):




5

or of formula (IV):



or of formula (V):











4. The compound of any one of claims 1-3, wherein R_2 is fluorine, chlorine or methyl, and wherein methyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile.





5. The compound of any one of claims 1-4, wherein R_2 is fluorine or chlorine or methyl, more particularly fluorine or chlorine, more particularly fluorine.





10 6. The compound of any one of claims 1-5, wherein R_4 is fluorine or methyl, and wherein methyl is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl.





15 7. The compound of any one of claims 1-3, which is chosen from among compounds 1-34:






Compound number	
1	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccccc2n1C3CC3</chem>
2	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccccc2n1F</chem>
3	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccccc2n1C(F)(F)F</chem>
4	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccc(C#N)cc2n1</chem>
5	 <chem>CCCC[C@H](O)Nc1nc(N)c2cc(ccc2n1)C3=NN=CO3</chem>






Compound number	
6	
7	
8	





Compound number	
9	 <chem>CCCC[C@H](CO)Nc1nc(N)c2cc(F)ccc12</chem>
10	 <chem>CCCC[C@H](CO)Nc1nc(N)c2cc(F)ccc12</chem>
11	 <chem>CCCC[C@H](C(=O)OC(C)C)Nc1nc(N)c2cc(C)ccc12</chem>
12	 <chem>CCCC[C@H](CO)Nc1nc(N)c2cc(OC)ccc12</chem>

Compound number	
13	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccc(F)cc2n1</chem>
14	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccc(C)cc2n1</chem>
15	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccccc2n1Cl</chem>
16	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccc(C)cc2n1</chem>

Compound number	
17	 <chem>CCCC[C@H](O)Nc1nc(N)c2cc(OC)ccc12</chem>
18	 <chem>CCCC[C@H](O)Nc1nc(N)c2cc(OC(=O))ccc12</chem>
19	 <chem>CCCC[C@H](O)Nc1nc(N)c2cc(F)c(F)cc12</chem>
20	 <chem>CCCCS[C@H](O)Nc1nc(N)c2cc(F)ccc12</chem>

Compound number	
21	
22	
23	
24	
25	

Compound number	
26	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccccc2n1C</chem>
27	 <chem>CCCC[C@H](O)Nc1nc(N)c2ccccc2n1C</chem>
28	 <chem>CC(C)[C@H](O)Nc1nc(N)c2ccccc2n1C</chem>
29	 <chem>CCCC(O)[C@H](O)Nc1nc(N)c2ccccc2n1C</chem>
30	 <chem>CCCC(O)[C@H](O)Nc1nc(N)c2ccccc2n1C</chem>

Compound number	
31	
32	
33	
34	

8. The compound of claim 7, which is chosen from among compounds 1, 2, 3, 4, 5, 7, 9, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24 and 26.

9. The compound of claim 7 or 8, which is chosen from among compounds 2, 13, 14, 15, 16, 21 and 23.
- 5 **10.** The compound of any one of claims 1-9, which is a TLR8 agonist, and which displays improved TLR8 agonism over TLR7.
- 10 **11.** The compound of any one of claims 1-10, which stimulate or activate a Th1 immune response, and/or which stimulate or activate cytokine production, more particularly the production of IL12.
- 15 **12.** A pharmaceutical composition, which comprises the compound of any one of claims 1-11 or a pharmaceutically acceptable salt, solvate or polymorph thereof, together with one or more pharmaceutically acceptable excipients, diluents or carriers.
- 20 **13.** The compound of any one of claims 1-11, or the pharmaceutical composition of claim 12, for use as medicament.
- 25 **14.** The compound of any one of claims 1-11, or the pharmaceutical composition of claim 12, for use in the treatment or prevention of viral infection, of a virus-induced disease, of cancer or of allergy, more particularly in the treatment or prevention of viral infection, of a virus-induced disease or of cancer, more particularly in the treatment or prevention of viral infection or of a virus-induced disease.
- 30 **15.** The compound of any one of claims 1-11, or the pharmaceutical composition of claim 12, for use in the treatment or prevention of chronic viral infection or of a disease induced by a chronic viral infection, more particularly for use in the treatment or prevention of HBV infection or of an HBV-induced disease, more particularly for use in the treatment or prevention of chronic HBV infection or of one or several diseases chosen from among liver fibrosis, liver inflammation, liver necrosis, cirrhosis, liver disease and hepatocellular carcinoma.